India Pharma Outlook Team | Wednesday, 13 August 2025
Senores Pharmaceuticals Limited, its wholly-owned US subsidiary Senores Pharmaceuticals, Inc., has entered into a pact to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) of Teva Pharmaceuticals USA, Inc.
The acquired ANDAs have a market value of about USD 38 million (MAT December 2024) and about USD 120 million (MAT June 2025), based on IQVIA and Symphony Health data. Senores will finance the acquisition through proceeds of its Initial Public Offering (IPO) as per the aims as laid out in its Red Herring Prospectus.
Senores Pharmaceuticals Limited is a research-based, international company with a mission of developing and producing a wide range of pharmaceutical products for distribution in the US, Canada, and other developed and developing economies. It owns 70 ANDAs and 27 CMO/CDMO business products that have received approval for distribution in the USA under its current portfolio. Senores Pharmaceuticals caters to more than 40 countries and is regulated by over 10 international governing bodies.
Also Read: Sartorius Invests in Nanotein to Boost Cell Therapy Tools
Senores has two formulation manufacturing plants — one located in Atlanta, USA (USFDA approved and DEA, TAA & BAA compliant) and the other in Chhatral, Ahmedabad (WHO-GMP approved). Senores also has two API manufacturing units in Gujarat at Chhatral and Naroda.
With three R&D facilities (one in USA and two in India), Senores is also expanding its pipeline of differentiated products, such as critical care injectables and Active Pharmaceutical Ingredients (APIs). The acquisition of Teva's ANDAs is likely to drive its growth path further in the regulated markets.
